Evidence map›Paper›PMID 42577588›Full record

ArticleERJ open research2026

Preventive intrapulmonary treatment with

Robert Brock, Laura Schaupp, André Schütte, Zhe Zhou-Suckow, Simone Butz, Jolanthe Schatterny, Selina Mayer, Angela Frank, Jan Philipp Mengel, Markus Weigel and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Robert BrockDepartment of Translational Pulmonology, Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg University, Heidelberg, Germany.
Laura SchauppDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
André SchütteDepartment of Translational Pulmonology, Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg University, Heidelberg, Germany.
Zhe Zhou-SuckowDepartment of Translational Pulmonology, Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg University, Heidelberg, Germany.
Simone ButzDepartment of Translational Pulmonology, Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg University, Heidelberg, Germany.
Jolanthe SchatternyDepartment of Translational Pulmonology, Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg University, Heidelberg, Germany.
Selina MayerDepartment of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
Angela FrankDepartment of Translational Pulmonology, Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg University, Heidelberg, Germany.
Jan Philipp MengelHessian State Office for Health and Care, Department II, Health and Infection Control, Dillenburg, Germany.
Markus WeigelInstitute of Medical Microbiology, Medical Microbiome-Metagenome Unit (M3U), Justus-Liebig University Giessen, Giessen, Germany.ORCID https://orcid.org/0000-0002-3140-3174
Torsten HainInstitute of Medical Microbiology, Medical Microbiome-Metagenome Unit (M3U), Justus-Liebig University Giessen, Giessen, Germany.ORCID https://orcid.org/0000-0003-0149-3137
Alexander DalpkeDepartment of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0003-1648-6618
Sébastien BoutinDepartment of Translational Pulmonology, Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg University, Heidelberg, Germany.
Marcus A MallDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-4057-2199

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic airway dysbiosis plays an important role in the pathogenesis of cystic fibrosis (CF) lung disease and may serve as a therapeutic target. However, studies investigating the effects of direct therapeutic targeting of the airway microbiome are lacking. In this study, we therefore used βENaC-overexpressing (βENaC-Tg) mice and determined the evolution of abnormal lung microbiota and effects of re-balancing bacterial communities on chronic airway inflammation and mucus plugging in this model of CF lung disease. Methods: The development of the respiratory microbiome was determined by 16S rRNA gene sequencing and the effects of preventive intranasal instillation of endogenous probiotic bacteria on the lung phenotype were determined in βENaC-Tg mice and wild-type littermates. Results: Neonatal βENaC-Tg mice developed severe respiratory dysbiosis characterised by an increase in the relative abundance of Conclusion: Preventive intrapulmonary application of the endogenous probiotic

Identifiers

PMID42577588
PMCPMC13454851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.